Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-23T04:20:17.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Rate of positive cultures necessitating definitive treatment in patients receiving empiric vancomycin therapy

Published online by Cambridge University Press:  12 June 2018

C. Dustin Waters Open the ORCID record for C. Dustin Waters [Opens in a new window]  and
Joshua Caraccio
C. Dustin Waters*
Affiliation:
Intermountain Healthcare McKay-Dee Hospital, Ogden, Utah
Joshua Caraccio
Affiliation:
Intermountain Healthcare Utah Valley Hospital, Provo, Utah (Present affiliation, Vigilanz, Minneapolis, Minnesota [J.C.].)
*
Author for correspondence: C. Dustin Waters, PharmD, BCPS(AQ-ID); 4403 Harrison Blvd, Ogden, UT 84403. E-mail: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Vancomycin is a commonly prescribed empiric antibiotic used when methicillin-resistant Staphylococcus aureus (MRSA) infection is suspected. In this study, we aimed to determine the rate of culture-positive infection requiring vancomycin therapy.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 8 , August 2018 , pp. 989 - 990
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Dantes, R, Mu, Y, Belflower, R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013;173:1970–1978.Google Scholar
2. Magill, SS, Edwards, JR, Beldavs, ZG, et al. Prevalence of antimicrobial use in US acute care hospitals, May–September 2011. JAMA 2014;312:1438–1446.Google Scholar
3. Kim, NH, Koo, HL, Choe, PG, et al. Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 2015;59:811–817.Google Scholar
4. Self, WH, Wunderink, RG, Williams, DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis 2016;63:300–309.Google Scholar
5. Jeng, A, Beheshti, M, Li, J, Nathan, R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 2010;89:217–226.Google Scholar
6. Stevens, DL, Bisno, AL, Chambers, HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:e10–e52.Google Scholar
7. Moran, GJ, Krishnadasan, A, Gorwitz, RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666–674.Google Scholar
8. Kullar, R, Leonard, SN, Davis, SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 2011;31:441–448.Google Scholar
9. Neely, MN, Youn, G, Jones, B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014;58:309–316.Google Scholar